超越传统治疗:ASGR1 引领高胆固醇血症管理的新时代
Jiali Song1, Yang Fang1, Xiuqin Rao1
1Department of Anesthesiology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China; Key Laboratory of Anesthesiology of Jiangxi Province, 1# Minde Road, Nanchang, Jiangxi 330006, PR China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|September 24, 2024
概括
亚洲糖蛋白受体1 (ASGR1) 是胆固醇代谢和低密度脂蛋白 (LDL) 清除的关键. 准ASGR1为管理高胆固醇血症和降低心血管疾病 (CVD) 风险提供了一种新的方法.
科学领域:
- 生物化学 生化学
- 心脏病学 心脏病学
- 分子生物学分子生物学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 高胆固醇血症是心血管疾病的重要危险因素.
- 目前的降脂疗法对许多患者来说是不够的.
研究的目的:
- 审查ASGR1在胆固醇代谢中的生物功能和调节机制.
- 探索ASGR1作为高胆固醇血症和相关心血管疾病的治疗点.
- 分析ASGR1在肝脏特定途径中的作用及其与心血管疾病风险的关联.
主要方法:
- 关于ASGR1研究的文献综述.
- 分析ASGR1在脂质平衡中的作用.
- 检查ASGR1变异及其对心血管疾病风险的影响.
主要成果:
- 主要在肝细胞上的ASGR1调节胆固醇代谢和LDL清除.
- ASGR1在肝脏特异性脂质通路中起着至关重要的作用.
- ASGR1变种与心血管疾病风险的改变有关.
结论:
- ASGR1是高胆固醇血症的一个有前途的治疗点.
- 了解ASGR1机制可能会导致新的心血管疾病治疗方法.
- 对ASGR1的进一步研究对于临床应用至关重要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
584
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
584
Cholesterol: Significance and Regulation
519
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
519
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Lipids: Dietary Sources and Requirements
708
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
708
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K


